Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Seasonal Allergic Rhinitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Seasonal Allergic Rhinitis - Pipeline Review, H2 2014', provides an overview of the Seasonal Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Seasonal Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seasonal Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seasonal Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seasonal Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Seasonal Allergic Rhinitis Overview 6 Therapeutics Development 7 Pipeline Products for Seasonal Allergic Rhinitis - Overview 7 Pipeline Products for Seasonal Allergic Rhinitis - Comparative Analysis 8 Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 9 Seasonal Allergic Rhinitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Seasonal Allergic Rhinitis - Products under Development by Companies 12 Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 13 Adamis Pharmaceuticals Corporation 13 FAES Farma SA 14 Glenmark Pharmaceuticals Ltd. 15 Mitsubishi Tanabe Pharma Corporation 16 Novartis AG 17 Ono Pharmaceutical Co., Ltd. 18 Shionogi & Co., Ltd. 19 VentiRx Pharmaceuticals, Inc. 20 Seasonal Allergic Rhinitis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 (azelastine hydrochloride + mometasone furoate) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 APC-3000 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 bepotastine besylate - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 bilastine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ONO-4053 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 S-555739 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VAK-694 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 VTX-1463 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Seasonal Allergic Rhinitis - Recent Pipeline Updates 41 Seasonal Allergic Rhinitis - Dormant Projects 44 Seasonal Allergic Rhinitis - Discontinued Products 45 Seasonal Allergic Rhinitis - Product Development Milestones 46 Featured News & Press Releases 46 Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 46 May 01, 2012: Ista Reports Positive Phase II Trial Results Of BEPOSONE Nasal Spray 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Number of Products under Development for Seasonal Allergic Rhinitis, H2 2014 7 Number of Products under Development for Seasonal Allergic Rhinitis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Seasonal Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 13 Seasonal Allergic Rhinitis - Pipeline by FAES Farma SA, H2 2014 14 Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 15 Seasonal Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 16 Seasonal Allergic Rhinitis - Pipeline by Novartis AG, H2 2014 17 Seasonal Allergic Rhinitis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 18 Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2014 19 Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Assessment by Combination Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Seasonal Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H2 2014 41 Seasonal Allergic Rhinitis - Dormant Projects, H2 2014 44 Seasonal Allergic Rhinitis - Discontinued Products, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
